Expression of the IR, coupled with the decrease in PKB/Akt and ERK1/2 activity in metformin-treated tumors, supports a model whereby lowering of systemic insulin leads to decreased IR stimulation on tumor cells and a subsequent reduction in downstream signaling, cell proliferation and survival (Figure 1B). Here, AKT1 is linked to neoplasm.